Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors.

Next Previous
Trial Profile

A Randomized, Placebo-controlled Study of the Effect of RO4607381 on Progression or Regression of Atherosclerotic Plaque in Patients With Coronary Heart Disease (CHD) Including Patients With Other CHD Risk Factors.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Atherosclerosis; Coronary disorders
  • Focus Therapeutic Use
  • Acronyms dal-PLAQUE
  • Sponsors Roche

Most Recent Events

  • 09 Sep 2011 Results published in the Lancet.
  • 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
  • 29 Aug 2011 Results were presented at the European Society of Cardiology Congress, according to a Roche media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top